We are delighted to announce the official start of LEGATO Project – EORTC – European Organisation for Research and Treatment of Cancer

The European Organisation for Research and Treatment of Cancer (EORTC), shared a post by LEGATO Project on LinkedIn, adding:

“We are delighted to announce the official start of LEGATO Project, a pragmatic phase III clinical trial focusing on recurrent Glioblastoma in collaboration with Syreon Research Institute.

LEGATO is one of three research projects coordinated by EORTC, alongside the DE-ESCALATE Project and STREXIT 2 Project, which has recently received funding from the Horizon Europe Programme. The study will have a duration of five years.

Read the article to learn more here.”

Quoting LEGATO Project’s post:

“Introducing the LEGATO project.

LEGATO Project is a clinical trial study conducted by an international group of researchers, funded by the European Union’s HORIZON Europe grant as part of the EU’s Cancer Mission. The EORTC – European Organisation for Research and Treatment of Cancer from Belgium, the Sapienza Università di Roma from Italy, brainstrust from the United Kingdom, the Medical University of Vienna, Austria, and Syreon Research Institute from Hungary are all working together, alongside medical experts in the field, to conduct a practice-changing study in the treatment of patients with recurrent glioblastoma. The study coordinator of the project is Professor Dr. Matthias Preusser (Medizinische Universität Wien), the co-coordinator is Professor Dr. Giuseppe Minniti (Univ. of Siena).

Results of the trial aim to demonstrate a significant improvement in overall survival when lomustine is combined with reirradiation in patients with recurrent glioblastoma compared to lomustine alone without adversely affecting the quality of survival.

If successful, the outcomes of the project will define a new evidence-based standard of care for recurrent glioblastoma. The proposed research could lead to improved patient survival and quality of life but also improve health system sustainability.

Find out more here.”

Sources: EORTC – European Organisation for Research and Treatment of Cancer/LinkedIn and LEGATO Project/LinkedIn